ProTren Probiotics is a professional-strength probiotic product line used by BioCorrect Nutrition to help our clients with digestive issues. ProTren specializes in manufacturing the highest pharmaceutical-grade quality probiotic supplements, setting a global standard of excellence in the dietary supplements industry.
Natasha Trenev introduced the term “probiotics” to the United States when she immigrated here in 1954. She and her company support scientific research throughout the world demonstrating the health benefits of their chosen bacteria strains.
- Lactobacillus acidophilus, NAS super strain
- Lactobacillus bulgaricus, LB-51 super strain
- Bifidobacterium bifidum, Malyoth super strain
- Bifidobacterium infantis, the most beneficial bacteria predominant in healthy infants.
Click Below to Purchase ProTren Probiotics
Why Choose ProTren Probiotics?
Leadership, Quality, Viability and Scientific Support. There’s a lot of hype from companies about numbers of different bacteria strains provided and who has more CFU’s in every capsule. When it comes to better health, simple is almost always best.
It’s a fact, probiotic bacteria strains don’t play nice with each other. They fight each other for dominance as they colonize in the intestines. Until one strain wins the dominance battle, the battle can cause gas and digestive distress. Fewer strains that colonize best in different locations in the digestive tract keep things simple and effective.
Three Is Best
ProTren focuses on three probiotic bacteria strains, all super strains chosen for their key properties. One that colonizes best in the upper or small intestine (Lactobacillus acidophilus). One that works best as food passes along the intestinal tract (Lactobacillus bulgaricus). Finally, one that colonizes best in the large intestines (colon) and finishes the digestive and elimination process (Bifidobacterium bifidum).
A forth strain only offered as a single strain formulation, Bifidobacterium infantis, is the predominant probiotic strain in healthy infants. It’s thought to have co-evolved with humans because of its unique ability to digest human breast milk oligosaccharides. It can be helpful for colicky infants with gas and gastric distress.
The good news is these single probiotic strains once established, fight against pathogenic flora, yeast and fungus that cause health issues. ProTren offers single strain probiotic options to selectively address individual regions of the digestive tract, and the 3-in-1 Trenev Trio which delivers the three key bacteria strains together to colonize separately along the digestive tract.
Viability – The Trenev Process
The Trenev Process® is a unique proprietary technology that ensures unmatched survivability and stability of the live probiotic bacteria. This cutting-edge technology uses an oil-matrix system to micro-enrobe the beneficial bacteria keeping them separated, non-competitive and virtually 100% protected from the stomach’s gastric juices.
Bacteria are commonly antagonistic and will fight for survival, therefore multi-strain probiotic products must be created in a way that maintains the separation of each individual strain. ProTren mixes together a maximum of only three organisms and uses this unique oil-matrix technology to keep them separate and non-competitive.
Trenev Trio Oil Matrix System
In addition to protecting the bacterial strains from one another, the oil-matrix also protects the live bacteria during their passage through the acidic stomach. This survivability has been validated through third-party testing by an internationally acclaimed European institute at pH 1.8 for 60-90 minutes. The protective oil-matrix delivery system results in virtually 100% survivability, for over an hour in corrosive stomach acid, of the three probiotic bacteria found in ProTren’s Trenev Trio and additional protection is provided by the two-piece hard gelatin capsule.
ProTren Probiotic Products
Every ProTren Probiotic order is shipped directly from ProTren using their Thermally Controlled Custom Shipping process to guarantee 100% potency of each probiotic strain through the printed expiration date. Note: there is a $12.95 cold packaging container and shipping fee for every order.
This is the amazing 3-in-1 Trenev Trio probiotic in its proprietary oil-matrix system.
It is our most potent probiotic – contains a minimum 30 billion of three potent, super strains of beneficial bacteria that work in combination to aid your digestion! The proprietary oil-matrix system protects bacteria viability as it passes through the stomach acid to colonize in your intestines.
Each capsule provides a minimum of:
- Lactobacillus acidophilus, NAS Super Strain, 5 billion cfu (colony forming units)
- Bifidobacterium bifidum, Malyoth Super Strain, 20 billion cfu
- Lactobacillus bulgaricus, LB-51 Super Strain, 5 billion cfu
SIZES: 15 capsule, 30 capsule, 60 capsule and 90 capsule bottles
ProTren BULGARICUM can help relieve occasional bloating, constipation and loose stool.*
Natren’s Lactobacillus bulgaricus LB-51 super strain is a transient bacteria that travels through the digestive tract with food as it is being processed by the body.
Each serving of BULGARICUM (either 1/2 tsp. (1 gram) powder or one capsule) provides a minimum of 2 billion cfu of Lactobacillus bulgaricus LB-51 transient super strain.
Recommended for adults and children over two years of age.
SIZES: 60 capsule and 90 capsule bottles
ProTren BIFIDONATE can help keep your colon in perfect working order.
ProTren BIFIDONATE powders and capsules are the most important beneficial bacteria for human health, according to Japanese research.
- A healthy intestinal flora
- Digestion and absorption
- Production of B vitamins
- Overall daily regime of probiotic intake
- Re-population of the colon with bacteria essential for good health
Don’t let a sluggish colon make you miserable. Residues and wastes can build up in the colon. BIFIDONATE can help keep your colon in perfect working order.
- Helps in liver function and detoxification.
- Helps in the production of B Vitamins in the gastrointestinal (GI) tract.
- Acts as a antimicrobial agent by producing acetic and lactic acid, to lower the pH of the intestines and inhibit undesirable bacteria.
- Helps to inhibit the colonization of the intestines by invading pathogens with which it competes for nutrients and attachment sites.
- May suppress harmful bacteria that are associated with age-related, geriatric diseases.
Bifidobacterium bifidum, Malyoth Super Strain, 2 billion cfu per serving
Recommended for adults and children over two years of age.
SIZES: 1.75 oz. powder, 3.0 oz. powder, 60 capsule and 90 capsule bottles
ProTren SUPERDOPHILUS aids in digestion and absorption.
ProTren SUPERDOPHILUS powders and capsules are the natural way to maintain a healthy intestinal flora no matter what season of the year.
- Optimized digestion
- General wellness
- Digestion of dairy products by assisting with lactose metabolism
- Small intestine health
ProTren SUPERDOPHILUS also aids in digestion and absorption. It is also a resident organism in the oral cavity, the vaginal tract and part of the urinary system.
- Helps destroy invading hostile bacteria by producing natural antibiotic substances.
- As an antimicrobial, may suppress undesirable microorganisms in the intestines, by some competitive means, e.g. production of lactic acid and other inhibitory substances.
- May help reduce levels of potentially harmful bacterial enzyme activity in the large intestine
- Helps lessen the production of hostile yeasts
- Helps maintain and support a healthy immune system
Lactobacillus acidophilus, NAS Super Strain, 2 billion cfu per capsule or 1/2 level teaspoon
Appropriate for vegans and recommended for adults and children over two years of age.
SIZES: 1.75 oz. powder, 3.0 oz. powder, 60 capsule, and 90 capsule bottles
Optimal digestion system for infants, expecting, or nursing mothers.
ProTren LIFE START PRO® Bifidobacterium infantis, the most beneficial bacteria predominant in healthy infants.
B. infantis is the predominant gut bacteria in healthy, breast-fed infants.
- Produce acetic and lactic acids and small amounts of formic acid from carbohydrates. These organic acids increase the acidity of the intestines, thereby inhibiting undesirable bacteria.*
- Optimized digestion*
- Prevent the colonization of the intestines by pathogens by competing for nutrients and attachment sites.*
- Assist nitrogen retention and weight gain in infants.*
- Inhibit bacteria that convert nitrates to potentially harmful nitrites.*
- Produce vitamins in the B-complex family.*
B. infantis is one of the most predominant bacteria found in the gut of healthy, full-term, breastfed infants. B. infantis was recently named the ‘champion colonizer of the infant gut’ by researchers at U.C. Davis because of its unique ability to digest human breast milk oligosaccharides. In a 1980 German study, B. infantis was the predominant beneficial bacteria found in infants. Alarmingly, since that time, researchers have found a decline in the numbers of B. infantis found in infants, including breast-fed infants.
Bifidobacteria and the specific substances they secrete can protect the intestinal mucosa in infants. When the microflora of infants becomes disturbed from oral antibiotic therapy, vaccinations, convalescence or sudden weather changes, the levels of Bifidobacteria decline and lower digestive health. The use of Bifidobacterium infantis NLS can help with the nutritional restoration of the intestinal microflora.
Bifidobacterium infantis NLS Super Strain, 1 billion cfu
SIZES: 1.25 ounce
BioCorrect Nutrition strives to provide our clients the Best-of-the-Best in quality, service and scientific support of our methods and recommendations. Below is a synopsis of scientific studies, research and explanations of how probiotic bacteria support better health.
- The concept of symbiosis: A survey of terminology used in description of associations of dis-similarly named organisms.
Rusch, V. s.l. : Microecology and Therapy, 1989, Vol. 19, pp. 33-59.
- Jung, GW, Tse JE, Guiha I, Rao J. Prospective, Randomized, Open-Label Trial Comparing the Safety, Efficacy, and
Tolerability of an Acne Treatment Regimen with and without a Probiotic Supplement and Minocycline in Subjects with Mild
to Moderate Acne. Journal of Cutaneous Medicine and Surgery 2013;Vol 17, 2: 114 -122.
- Axelsson, L. Lactic acid bacteria: Classification and physiology 2nd edition. Lactic acid bacteria: microbiology and
functional aspects. Basel : Marcel Dekker Inc, 1998, pp. 1-72.
- Casein degradation and amino acid liberation in milk by two highly proteolytic strains of lactic acid bacteria. Chebbi, N.
B., H. Chander, and B. Ranganathan. 3, s.l. : Acta microbiologica polonica, 1976, Vol. 26, pp. 281-284.
- De Vuyst, L. and Vandamme, Eerick J. Antimicrobial Potential of Lactic Acid Bacteria. Bacteriocins of Lactic Acid
Bacteria. London : Springer US, 1994, pp. 91-142.
- Ouwehand, Arthur C. Antimicrobial components from lactic acid bacteria. Lactic acid bacteria: microbiology and
functional aspects. New York : Marcel Dekker Inc., 1998, pp. 139-160.
- Cell-wall-bound proteinase of Lactobacillus delbrueckii subsp. lactisACA-DC 178: characterization and specificity for
β-casein. Tsakalidou, E., R. Anastasiou, I. Vandenberghe, Jozef Van Beeumen, and G. Kalantzopoulos. 5, s.l. :
Applied and environmental microbiology, 1999, Applied and environmental microbiology, Vol. 65.
- Role of bifidobacteria in nutrition, medicine and technology. Arunachalam, Kantha D. 10, s.l. : Nutrition research, 1999,
Nutrition research, Vol. 19, pp. 1559-1597.
- Bifidobacteria and probiotic action. [book auth.] J. Ballongue. [ed.] and A. von Wright S. Salminen. Lactic acid bacteria.
New York : Marcel Dekkar, 1993, pp. 357-428.
- Probiotic spectra of lactic acid bacteria (LAB). Naidu, A. S., W. R. Bidlack, and R. A. Clemens. 1, s.l. : Critical reviews
in food science and nutrition, 1999, Vol. 39, pp. 13-126.
- Rasic, Jeremija Lj. and Kurmann, Joseph A. Bifidobacteria and Their Role – Microbiological, Nutritional-Physiological,
Medical and Technological Aspects and Bibliography. Basel : Birkhauser Verlag, 1983.
- Bifidobacterium Bifidum administration in humans: A controlled clinical study in liver cirrhosis. Muting, Dieter, et al.
s.l. : Microecology and Therapy, 1986, Microecology and Therapy, Vol. 16, pp. 271-272.
- The effect of bacterium bifidum on intestinal bacterial flora and toxic protein metabolites in chronic liver disease.
Muting, Dieter, W. Eschrich, and J. P. Mayer. 5, s.l. : American journal of proctology, 1968, Vol. 19, p. 336.
- Inhibition of Candida albicans by Lactobacillus acidophilus: evidence for the involvement of a peroxidase system.
Fitzsimmons N, Berry D.R. s.l. : Microbios, 1994, Microbios, Vol. 80, pp. 125-133.
- Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Hilton, Eileen, Henry
D. Isenberg, Phyllis Alperstein, Kenneth France, and Michael T. Borenstein. 5, s.l. : Annals of Internal Medicine, 1992,
Annals of Internal Medicine, Vol. 116, pp. 353-357.
- Control of the microbial flora of the vagina by H202-generating lactobacilli. Klebanoff, S. J., S. L. Hillier, D. A. Eschenbach,
and A. M. Waltersdorph. 1, s.l. : Journal of Infectious Diseases, 1991, Journal of Infectious Diseases , Vol.
164, pp. 94-100.
- Influence of lactobacilli on the adhesion ofStaphylococcus aureus and Candida albicans to fibers and epithelial cells.
Reid, G., C. Tieszer, and D. Lam. 3, s.l. : Journal of industrial microbiology, 1995, Journal of industrial microbiology, Vol.
15, pp. 248-253.
- Influence of yogurt and acidophilus yogurt on serum cholesterol levels in mice. Akalin, A. Sibel, Siddik Gönç, and
Selmin Düzel. 11, s.l. : Journal of dairy science, 1997, Journal of dairy science, Vol. 80, pp. 2721-2725.
- Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic
humans. Anderson, James W., and Stanley E. Gilliland. 1, s.l. : Journal of the American College of Nutrition, 1999,
Journal of the American College of Nutrition, Vol. 18, pp. 43-50.
- Anticholesteremic property of Lactobacillus acidophilus yogurt fed to mature boars. Danielson, A. D., E. R. Peo Jr,
K. M. Shahani, A. J. Lewis, P. J. Whalen, M. A. Amer, and Win Butler. “. s.l. : Journal of Animal Science, 1989, Journal
of Animal Science, Vol. 67, pp. 966-974.
- Hypocholesterolemic Action of Lactobacillus acidophilus ATCC 43121 and Calcium in Swine with Hypercholesterolemia
Induced by Diet. De Rodas, B. Z., S. E. Gilliland, and C. V. Maxwell. 12, s.l. : Journal of dairy science, 1996, Journal of
dairy science, Vol. 79, pp. 2121-2128.
- Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on cholesterol metabolism in
ratsfed on a fat-and cholesterol-enriched diet. Fukushima, Michihiro, and Masuo Nakano. 6, s.l. : British Journal of
Nutrition, 1996, British Journal of Nutrition, Vol. 76, pp. 857-867.
- Factors to Consider When Selecting a Culture of Lactobacillus acidophilus as a Dietary Adjunct to Produce a Hypocholesterolemic
Effect in Humans. Gilliland, S. E., and D. K. Walker. 4, 1990, Journal of dairy science, Vol. 73, pp. 905- 911.
- Assimilation of cholesterol by Lactobacillus acidophilus. Gilliland, S. E., C. R. Nelson, and C. Maxwell. 2, s.l. : Applied
and Environmental Microbiology, 1985, Applied and Environmental Microbiology, Vol. 49, pp. 377-381.
- Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mitall, Brij K., and
Satyendra K. Garg. 3, s.l. : Critical reviews in microbiology, 1995, Critical reviews in microbiology, Vol. 21, pp. 175-214.
- Inhibition of Candida albicans by Lactobacillus acidophilus. Collins, E. B., and Pamela Hardt. 5, s.l. : Journal of dairy
science, 1980, Journal of dairy science, Vol. 63, pp. 830-832.
- Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk
intake. Link-Amster, H., F. Rochat, K. Y. Saudan, O. Mignot, and J. M. Aeschlimann. s.l. : FEMS immunology and
medical microbiology, 1994, FEMS immunology and medical microbiology, Vol. 10, pp. 56-64.
- Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and
Lactobacillus acidophilus. Perdigon, Gabriela, M. E. De Macias, S. Alvarez, G. Oliver, and A. Pesce de Ruiz Holgado.
1, s.l. : Immunology, 1988, Immunology, Vol. 63.
- Enhancement of Immune Response in Mice Fed with Streptococcus thermophilus and Lactobacillus acidophilus.
Perdigon, G., M. E. Nader de Macias, S. Alvarez, G. Oliver, and A. A. Pesce de Ruiz Holgado. 5, s.l. : Journal of dairy
science, 1987, Journal of dairy science, Vol. 70, pp. 919-926.
- Alm, L and Robinson, R. K. The therapeutic effects of various cultures-an overview. Therapeutic properties of fermented milks. London: Elsevier Science Publishers Ltd., 1991, pp. 45-64.
- The effects of lactulose-sweetened yoghurt on the rate of gastric emptying and intestinal transit in healthy human
volunteers. Porkka, L., E. Salminen, and S. Salminen. 3, s.l. : Zeitschrift für Ernährungswissenschaft, 1988, Vol. 27,
- Effect of viable starter culture bacteria in yogurt on lactose utilization in humans. Gilliland, Stanley E., and H. S. Kim.
1, s.l. : Journal of Dairy Science, 1984, Journal of Dairy Science, Vol. 67, pp. 1-6.
- Lactic acid bacteria and human health. Gorbach, Sherwood L. 1, s.l. : Annals of Medicine, 1990, Annals of Medicine,
Vol. 22, pp. 37-41.
- Lactobacillus acidophilus as a Dietary Adjunct for Milk to Aid Lactose Digestion in Humans. Kim, Hyung Soo, and
Stanley E. Gilliland. 5, s.l. : Journal of dairy science, 1983, Journal of dairy science, Vol. 66, pp. 959-966.
- Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans. Lin,
Meei-Yn, Dennis Savaiano, and Susan Harlander. 1, s.l. : Journal of dairy science, 1991, Journal of dairy science, Vol.
74, pp. 87-95.
- Strains and species of lactic acid bacteria in fermented milks (yogurts): effect on in vivo lactose digestion. Martini,
Margaret C., Eric C. Lerebours, Wei-Jin Lin, Susan K. Harlander, Nabil M. Berrada, Jean M. Antoine, and Dennis
A. Savaiano. 6, s.l. : The American journal of clinical nutrition, 1991, The American journal of clinical nutrition, Vol. 54, pp.
- Alleviation of lactose malabsorption from sweet acidophilus milk. McDonough, F. E., N. P. Wong, A. Hitchins, and
C. E. Bodwell. 2, s.l. : The American journal of clinical nutrition, 1985, The American journal of clinical nutrition, Vol. 42,
pp. 345- 346.
- Effect of Milks Inoculated with Lactobacillus acidophilus or a Yogurt Starter Culture in Lactose-Maldigesting Children.
Montes, R. G., T. M. Bayless, J. M. Saavedra, and J. A. Perman. 8, s.l. : Journal of dairy science, 1995, Journal of dairy
science, Vol. 78, pp. 1657-1664.
- Improvement of Lactose Digestion by Humans Following Ingestion of Unfermented Acidophilus Milk: Influence of
Bile Sensitivity, Lactose Transport, and Acid Tolerance of Lactobacillus acidophilus. Mustapha, Azlin, Tianan Jiang,
and Dennis A. Savaiano. 8, s.l. : Journal of dairy science, 1997, Journal of dairy science, Vol. 80, pp. 1537-1545.
- Genetics of bacteriocins produced by lactic acid bacteria. Klaenhammer, Todd R. 1, s.l. : FEMS microbiology reviews,
1993, Vol. 12, pp. 39-85.
- In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. Midolo, P. D.,
J. R. Lambert, R. Hull, F. Luo, and M. L. Grayson. 4, s.l. : Journal of Applied Microbiology, 1995, Journal of Applied
Microbiology, Vol. 79, pp. 475-479.
- Inhibition of Shigella sonnei by Lactobacillus casei and Lact. acidophilus. Macías, María E. Nader, María C. Apella,
Nora C. Romero, Silvia N. González, and G. Oliver. 5, s.l. : Journal of Applied Microbiology, 1992, Journal of Applied
Microbiology, Vol. 73, pp. 407-411.
- Biosynthesis of bacteriocins in lactic acid bacteria. Nes, Ingolf F., Dzung Bao Diep, Leiv Sigve Håvarstein, May
Bente Brurberg, Vincent Eijsink, and Helge Holo. 2-4, s.l. : Antonie van Leeuwenhoek, 1996, Antonie van Leeuwenhoek,
Vol. 70, pp. 113-128.
- Growth inhibition of food‐borne pathogens by lactic and acetic acids and their mixtures. Adams, M. R., and C. J. Hall.
3, s.l. : International Journal of Food Science & Technology, 1988, International Journal of Food Science & Technology,
Vol. 23, pp. 287-292.
- Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion
by enterovirulent bacteria. Bernet, M. F., D. Brassart, J. R. Neeser, and A. L. Servin. 4, s.l. : Gut, 1994, Gut, Vol. 35, pp.
- Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. Bhatia, S. J., N. Kochar, P. Abraham,
N.G. Nair, and A.P. Mehta. 10, s.l. : Journal of clinical microbiology, 1989, Journal of clinical microbiology, Vol. 27,
- Yoghurt: Scientific grounds, technology, manufacture and preparations. Rasic, Jeremija Lj. and Kurman, Joseph A.
Denmark : Technical Dairy Publishing House, 1978, Yoghurt: Scientific grounds, technology, manufacture and preparations.
- Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic
bacteria in cultured human intestinal cells. Coconnier, Marie-Helene, Marie-Francoise Bernet, Gilles Chauviere, and
Alain L. Servin. s.l. : Journal of diarrhoeal diseases research, 1993, Journal of diarrhoeal diseases research, Vol. 11, pp.
- Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain
LB decreases bacterial invasion. Coconnier, Marie-Hélène, Marie-Françoise Bernet, Sophie Kernéis, Gilles Chauvière,
Jacky Fourniat, and Alain L. Servin. 3, s.l. : FEMS Microbiology Letters, 1993, FEMS Microbiology Letters, Vol.
110, pp. 299-305.
- Inhibition of bacterial pathogens by lactobacilli. Dembele, Tiecoura, Vlastimil Obdrálek, and Miroslav Votava. 3,
s.l. : Zentralblatt für Bakteriologie, 1998, Zentralblatt für Bakteriologie, Vol. 288, pp. 395-401.
- The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance (s) active in
vitro and in vivo. Bernet-Camard, Marie-Francoise, Vanessa Lievin, Dominique Brassart, Jean-Richard Neeser,
Alain L. Servin, and Sylvie Hudault. 7, s.l. : Applied and environmental microbiology, 1997, Applied and environmental
microbiology, Vol. 63, pp. 2747-2753.
- Isolation and characterization of two bacteriocins of Lactobacillus acidophilus LF221. Bogovič-Matijašić, Bojana,
Irena Rogelj, I. F. Nes, and H. Holo. 5, s.l. : Applied microbiology and biotechnology, 1998, Applied microbiology and
biotechnology, Vol. 49, pp. 606-612.
- Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Boris,
Soledad, Juan E. Suárez, Fernando Vázquez, and Covadonga Barbés. 5, s.l. : Infection and immunity, 1998,
Infection and immunity, Vol. 66, pp. 1985-1989.
- Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Coconnier, Marie-Helene, Vanessa
Liévin, Marie-Francoise Bernet-Camard, Sylvie Hudault, and Alain L. Servin. 5, s.l. : Antimicrobial agents and
chemotherapy, 1997, Vol. 41, pp. 1046-1052.
- Antimicrobial effect of Lactobacillus acidophilus and Lactobacillus delbrueckii subsp. bulgaricus against Heliobacter
pylori in vitro. Rasic, Jeremija, et al. 4, s.l. : Arch. Gastroenterohepatol, 1995, Arch. Gastroenterohepatol, Vol. 14, pp.
- Rasic, Jeremija. Laboratory Studies. 1989-1993.
- Natural antibiotic activity of Lactobacillus acidophilus and bulgaricus. III. Production and partial purification of bulgarican
from Lactobacillus bulgaricus. Reddy, G. V., K. M. Shahani, B. A. Friend, and R. C. Chandan. s.l. : Cultured Dairy
Products Journal, 1983, Cultured Dairy Products Journal , pp. 15-19.
- Natural antibiotic activity of Lactobacillus acidophilus and Bulgaricus. II. Isolation of acidophilin from Lactobacillus
acidophilus [Milk]. Shahani, K. M., J. R. Vakil, and A. Kilara. 2, s.l. : Cultured Dairy Products Journal, 1977, Cultured
Dairy Products Journal, Vol. 12, pp. 8-11.
- Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Wagner, R. Doug, Carey Pierson,
Thomas Warner, Margaret Dohnalek, Jeffrey Farmer, Lisa Roberts, Milo Hilty, and Edward Balish. 1, s.l. : Infection
and immunity, 1997, Infection and immunity, Vol. 65.
- Helicobacter pylori – Fact Sheet for Health Care Providers. CDC: July 1998